Small-Molecule Sarco/Endoplasmic Reticulum Ca²⁺-ATPase Activators Reverse Methylglyoxal-Induced Inhibition through...

Area of Science:

• Biochemistry
• Cell Biology
• Endocrinology

Background:

• Diabetes mellitus is characterized by beta-cell dysfunction, partly due to impaired endoplasmic reticulum (ER) calcium (Ca2+) homeostasis.
• Methylglyoxal (MGX), a diabetic byproduct, induces oxidative stress and inhibits sarco/endoplasmic reticulum Ca2+-ATPase (SERCA), crucial for ER Ca2+ regulation.

Purpose of the Study:

• To investigate novel synthetic compounds for their ability to activate SERCA and restore ER Ca2+ homeostasis.
• To elucidate the mechanism of SERCA protection against MGX-induced inhibition, distinguishing between direct activation and antioxidant effects.

Main Methods:

• Synthesis and testing of novel SERCA activators.
• Assessment of SERCA activity following MGX exposure in the presence of activators.
• Evaluation of compound antioxidant properties (radical scavenging, lipid peroxidation inhibition).

Main Results:

• Novel compounds directly stimulated SERCA activity and restored function inhibited by MGX.
• SERCA function recovery correlated with activator potency, not antioxidant capacity.
• Direct SERCA activation alone was sufficient to reverse MGX-induced oxidative damage.

Conclusions:

• Direct pharmacological activation of SERCA is a viable strategy to preserve ER Ca2+ homeostasis in diabetes.
• This approach offers a mechanistically distinct therapeutic avenue independent of general antioxidant effects.
• Targeting SERCA directly presents a promising therapeutic strategy for managing diabetic complications.